Age, median (years, range) | 64 (45–86) |
Gender | |
 Male | 20 (55.6) |
 Female | 16 (44.4) |
Location | |
 Sigmoid colon | 21 (58.4) |
 Ascending colon | 12 (33.3) |
 Transverse colon | 3 (8.3) |
Clinical tumor depth | |
 T3 | 13 (36.1) |
 T4a | 13 (36.1) |
 T4b | 10 (27.8) |
Clinical lymph node metastasis | |
 N0 | 1 (2.7) |
 N1 | 16 (44.5) |
 N2 | 19 (52.8) |
UICC staging | |
 IIC | 1 (2.7) |
 IIIB | 15 (41.7) |
 IIIC | 20 (55.6) |
Pretreatment CEA (ng/mL) | |
 ≦ 5 | 19 (52.8) |
  > 5 | 17 (47.2) |
Ileosotmy/colostomy prior to therapy | |
 Yes | 19 (52.7) |
 No | 17 (47.3) |
Radiotherapy (dose/fractions) | |
 45 Gy/25 | 6 (16.7) |
 50 Gy/25 | 25 (69.5) |
 50.4Gy/28 | 4 (11.1) |
 46.8Gy/26 | 1 (2.7) |
Post-operative chemotherapy | |
 FOLFOX | 15 (41.7) |
 UFUR | 11 (30.6) |
 Capecitabine | 5 (13.9) |
 FOLFIRI | 2 (5.4) |
 None | 3 (8.4) |
BMI kg/m2 (median) (range) | 22.4 (14.8–41.8) |
RT-Surgery interval week (median) (range) | 11 (6–25) |